Skip to main content

BTIG Reaffirms Their Buy Rating on Solventum Corporation (SOLV)

Tipranks - Tipranks - Sat Feb 28, 6:44AM CST

BTIG analyst Ryan Zimmerman maintained a Buy rating on Solventum Corporation yesterday and set a price target of $100.00. The company’s shares closed yesterday at $76.94.

Claim 50% Off TipRanks Premium

Zimmerman covers the Healthcare sector, focusing on stocks such as Solventum Corporation, Globus Medical, and Organogenesis Holdings. According to TipRanks, Zimmerman has an average return of 0.7% and a 44.74% success rate on recommended stocks.

Currently, the analyst consensus on Solventum Corporation is a Strong Buy with an average price target of $96.14, a 24.95% upside from current levels. In a report released today, KeyBanc also maintained a Buy rating on the stock with a $99.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Solventum Corporation’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.1 billion and a net profit of $1.27 billion. In comparison, last year the company earned a revenue of $2.08 billion and had a net profit of $122 million

Read More on SOLV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).